Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.

about

Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.

Item

http://www.wikidata.org/entity/Q39455425

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Antisense oligodeoxynucleotide ...... el in breast cancer treatment.

@en

Antisense oligodeoxynucleotide ...... el in breast cancer treatment.

@nl

type

Item

label

Antisense oligodeoxynucleotide ...... el in breast cancer treatment.

@en

Antisense oligodeoxynucleotide ...... el in breast cancer treatment.

@nl

prefLabel

Antisense oligodeoxynucleotide ...... el in breast cancer treatment.

@en

Antisense oligodeoxynucleotide ...... el in breast cancer treatment.

@nl

P1476

Antisense oligodeoxynucleotide ...... el in breast cancer treatment.

@en

P2093

Haifeng Duan

http://www.w3.org/2001/XMLSchema#string

Junzhong Sun

http://www.w3.org/2001/XMLSchema#string

Santai Song

http://www.w3.org/2001/XMLSchema#string

Yin Xu

http://www.w3.org/2001/XMLSchema#string

Zuze Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting.

Antisense therapeutics: from theory to clinical practice.

Targeting transcription factors for cancer therapy.

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.

Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.

Advances in the treatment of breast cancer.

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.

P304

1167-1172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/13880209.2011.575792

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22014264

http://www.w3.org/2001/XMLSchema#string